Setmelanotide

Setmelanotide is a synthetic cyclic octapeptide that acts as a selective agonist of the melanocortin-4 receptor (MC4R). It is administered as a once-daily subcutaneous injection. The molecule was developed by Rhythm Pharmaceuticals specifically as a targeted therapy for genetic and acquired diseases of the hypothalamic MC4R pathway. The structure is based on alpha-MSH (the natural MC4R agonist) with modifications to increase receptor selectivity, extend half-life, and reduce off-target activity at other melanocortin receptors. FDA approval pathway began November 2020 for POMC, PCSK1, and LEPR deficiency, expanded June 2022 for Bardet-Biedl syndrome, expanded December 2024 to include children as young as 2 years, and expanded March 19, 2026 for acquired hypothalamic obesity.

The hypothalamic MC4R pathway is the central regulator of appetite and energy expenditure in the brain. The pathway begins with leptin signaling to POMC neurons in the arcuate nucleus of the hypothalamus. POMC neurons produce alpha-MSH, which binds MC4R on second-order neurons to reduce hunger and increase energy expenditure. Defects anywhere in this pathway (POMC gene mutations, PCSK1 mutations preventing POMC cleavage, LEPR mutations preventing leptin signaling, MC4R mutations themselves) produce severe early-onset obesity with hyperphagia (pathological hunger).

The Rhythm Pharmaceuticals development strategy has been to address rare genetic diseases of the MC4R pathway as a precision-medicine commercial model. The patient populations are small (POMC, PCSK1, and LEPR deficiencies together affect 600 to 2,500 people in the United States, Bardet-Biedl syndrome approximately 2,000 to 5,000, and acquired hypothalamic obesity approximately 10,000). The orphan disease status supports premium pricing and orphan drug exclusivity.

The Approved Indications

Setmelanotide has progressed through four FDA approval milestones.

POMC, PCSK1, and LEPR deficiency (FDA approval November 2020). Initial approval. Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing. The first-ever FDA-approved therapy for these rare genetic obesity diseases.

Bardet-Biedl syndrome (FDA approval June 16, 2022). Patients 6 years and older with obesity due to Bardet-Biedl syndrome. The Phase 3 trial in 31 patients showed 7.9 percent BMI reduction at 1 year.

Pediatric expansion (FDA approval December 20, 2024). Lowered the minimum age for the approved indications (BBS and POMC/PCSK1/LEPR deficiency) to 2 years.

Acquired hypothalamic obesity (FDA approval March 19, 2026). Adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity. The most recent label expansion. Based on the TRANSCEND Phase 3 trial.

The TRANSCEND Phase 3 Trial

The TRANSCEND trial supported the 2026 acquired hypothalamic obesity approval.

Patient population. Adults and pediatric patients with acquired hypothalamic obesity from hypothalamic injury (craniopharyngioma surgery, brain tumor treatment, traumatic brain injury, stroke, inflammation). Approximately 10,000 people are estimated to have acquired HO in the United States.

Primary endpoint. Change in BMI at 52 weeks versus placebo.

Primary result. Setmelanotide produced a -18.8 percent placebo-adjusted BMI difference at 52 weeks (mean BMI change -16.4 percent on setmelanotide versus +2.4 percent on placebo, p<0.0001). The magnitude is among the largest seen in any FDA-approved obesity therapy.

Hunger reduction. Among patients aged 12 years and older, the "most hunger" score showed a 2.5-point weekly reduction on setmelanotide versus 1.3 points on placebo (p=0.0015). The hunger reduction is clinically meaningful for patients with severe hyperphagia.

Safety. Consistent with the established setmelanotide safety profile. Skin hyperpigmentation, injection-site reactions, nausea, and the standard MC4R-class effects.

EMA approval (May 1, 2026). The European Commission granted marketing authorization for the acquired hypothalamic obesity indication on May 1, 2026, providing EU access alongside the US approval.

Setmelanotide acts on the melanocortin-4 receptor (MC4R) in the hypothalamus and other neural tissues.

MC4R agonism in the hypothalamus. The MC4R is part of the central regulator of appetite, caloric intake, and energy expenditure. MC4R activation in the paraventricular nucleus and other hypothalamic regions reduces hunger signals and increases energy expenditure. The downstream effect is reduced food intake and increased calorie burn, producing weight loss.

Restoration of disrupted pathway function. In POMC deficiency, the lack of endogenous alpha-MSH leaves MC4R unstimulated. Setmelanotide directly activates MC4R, bypassing the defective POMC step. Similar logic applies to PCSK1 deficiency (where POMC cannot be cleaved to alpha-MSH) and LEPR deficiency (where leptin cannot activate POMC neurons).

Bardet-Biedl syndrome. BBS is a multi-system ciliopathy with hypothalamic dysfunction that disrupts the MC4R pathway through abnormal cilia function in POMC neurons. Setmelanotide bypasses the upstream dysfunction by directly activating MC4R.

Acquired hypothalamic obesity. Hypothalamic injury (from craniopharyngioma surgery, brain tumor treatment, traumatic brain injury, stroke, or inflammation) damages POMC neurons and the MC4R pathway. Setmelanotide restores MC4R activation in the residual hypothalamic tissue.

Reduction of hyperphagia. Across all approved indications, the primary clinical effect is reduction of pathological hunger (hyperphagia). The hunger reduction supports both weight loss and quality-of-life improvements.

Receptor selectivity. Setmelanotide has highest affinity for MC4R but also binds MC1R (the pigmentation receptor), producing the characteristic skin hyperpigmentation that develops in many treated patients.

The mechanism is fundamentally different from GLP-1 agonists (which target the GLP-1 receptor in pancreas and gut) and amylin analogs (which target amylin receptors). Setmelanotide is precision therapy for specific MC4R pathway diseases rather than general obesity therapy.

Setmelanotide has progressed through four FDA approval milestones.

POMC, PCSK1, and LEPR deficiency (FDA approval November 2020). Initial approval. Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing. The first-ever FDA-approved therapy for these rare genetic obesity diseases.

Bardet-Biedl syndrome (FDA approval June 16, 2022). Patients 6 years and older with obesity due to Bardet-Biedl syndrome. The Phase 3 trial in 31 patients showed 7.9 percent BMI reduction at 1 year.

Pediatric expansion (FDA approval December 20, 2024). Lowered the minimum age for the approved indications (BBS and POMC/PCSK1/LEPR deficiency) to 2 years.

Acquired hypothalamic obesity (FDA approval March 19, 2026). Adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity. The most recent label expansion. Based on the TRANSCEND Phase 3 trial.

Regulatory status

United States (FDA). Four sequential approvals between 2020 and 2026 covering POMC/PCSK1/LEPR deficiency, Bardet-Biedl syndrome, pediatric expansion to age 2, and acquired hypothalamic obesity. Active commercial product with broad rare-disease coverage.

European Union (EMA). Approved through centralized procedure for the same indications. Most recent EU approval (acquired HO) on May 1, 2026.

United Kingdom (MHRA). Approved for the established indications.

Orphan Drug Designation. All four approved indications are rare diseases with orphan drug designation in the US and EU.

WADA status. Setmelanotide is on the WADA Prohibited List under section S5 (Diuretics and Masking Agents) due to weight-affecting properties, and is also covered by section S2 considerations. Use in competitive sport is a doping violation. Approved clinical use through legitimate prescribing channels receives Therapeutic Use Exemptions.

Compounding. Setmelanotide is not on the FDA Category 2 bulks list. Active commercial product status under Rhythm Pharmaceuticals.

Setmelanotide has progressed through four FDA approval milestones.

POMC, PCSK1, and LEPR deficiency (FDA approval November 2020). Initial approval. Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing. The first-ever FDA-approved therapy for these rare genetic obesity diseases.

Bardet-Biedl syndrome (FDA approval June 16, 2022). Patients 6 years and older with obesity due to Bardet-Biedl syndrome. The Phase 3 trial in 31 patients showed 7.9 percent BMI reduction at 1 year.

Pediatric expansion (FDA approval December 20, 2024). Lowered the minimum age for the approved indications (BBS and POMC/PCSK1/LEPR deficiency) to 2 years.

Acquired hypothalamic obesity (FDA approval March 19, 2026). Adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity. The most recent label expansion. Based on the TRANSCEND Phase 3 trial.

The setmelanotide safety profile is well characterized through multi-year clinical experience.

Skin hyperpigmentation. Common and characteristic effect due to MC1R cross-activation. Approximately 50 to 60 percent of patients develop darkening of skin pigmentation, particularly in sun-exposed areas. Mole darkening and new mole development. Skin examination is recommended at treatment initiation and periodically thereafter. The effect is dose-dependent and generally cosmetic rather than pathological.

Disturbances in sexual arousal. Reported in some patients. Mechanism involves MC4R effects on sexual function pathways. Generally mild.

Depression and suicidal ideation. Reports of psychiatric symptoms including depression and suicidal ideation in some patients. Standard psychiatric monitoring is recommended.

Injection-site reactions. Common with daily subcutaneous administration. Generally mild.

Nausea, vomiting, diarrhea. Gastrointestinal effects in some patients. Generally mild to moderate.

Headache. Reported at moderate rates.

Skin reactions. Beyond pigmentation, some patients develop hypersensitivity reactions.

Spontaneous penile erections in male children. Reported as a class effect of MC4R agonists. Generally self-limited.

The safety profile is acceptable for the indicated rare diseases where the alternatives are severe hyperphagia and progressive obesity with substantial health consequences. The use is restricted to specialized prescribing centers with expertise in rare endocrine and metabolic disease.

Setmelanotide is fundamentally different from the broader obesity pharmacotherapy class.

Setmelanotide vs Semaglutide (Wegovy). Different mechanism (MC4R agonism vs GLP-1 receptor agonism) and different patient populations. Setmelanotide is for rare genetic and acquired MC4R pathway diseases. Semaglutide is for general obesity. The two address different clinical situations.

Setmelanotide vs Tirzepatide (Zepbound). Same comparison as semaglutide. Tirzepatide targets GLP-1 and GIP receptors. Setmelanotide targets MC4R. Different populations and indications.

Setmelanotide vs MC4R variant patients. Patients with MC4R mutations (rather than upstream POMC/PCSK1/LEPR mutations) have a defective receptor that setmelanotide cannot effectively activate. The drug is not indicated for MC4R variant patients.

Setmelanotide vs Bremelanotide (Vyleesi). Bremelanotide is a melanocortin agonist with broader receptor activity (MC1R, MC3R, MC4R) FDA-approved for hypoactive sexual desire disorder. Different indication and structure. The MC4R activity overlaps but setmelanotide is more selective.

Setmelanotide vs Alpha-MSH and Melanotan II. Alpha-MSH is the natural ligand. Melanotan II is an unregulated research-chemical analog used for skin tanning. Setmelanotide is the FDA-approved MC4R-selective option for the approved indications.

The targeted nature of setmelanotide for specific rare diseases distinguishes it from the broader obesity pharmacotherapy class. The molecule is precision medicine for specific MC4R pathway diseases.